Under-representation of older Indian persons with cancer in clinical trials
Vanita Noronha, Kumar Prabhash(Homi Bhabha National Institute), Zoya Peelay(Cancer Institute (WIA)), Sheila Nainan Myatra(Homi Bhabha National Institute), Jai Prakash Agarwal(Tata Memorial Hospital), Richa Vaish(Homi Bhabha National Institute), Vijay Patil, Nandini Menon(Homi Bhabha National Institute), Vikram Gota(Homi Bhabha National Institute), Shailesh V. Shrikhande(Homi Bhabha National Institute), Sarbani Ghosh Laskar(Tata Memorial Hospital), Manali Kolkur(Homi Bhabha National Institute), Amey Oak(Twitter (United States)), Vijayalakshmi Mathrudev, Rajendra Badwe(Tata Memorial Hospital), Vedang Murthy(Homi Bhabha National Institute), Anant Ramaswamy(Homi Bhabha National Institute), Nita Nair(Tata Memorial Hospital), Sabita Jiwnani(Homi Bhabha National Institute), Pankaj Chaturvedi(Tata Memorial Hospital), Vikas Ostwal(Homi Bhabha National Institute), Sudeep Gupta(Homi Bhabha National Institute), Supriya Chopra(Tata Memorial Hospital), Devendra Chaukar(Tata Memorial Hospital), Sudhir Nair(Homi Bhabha National Institute), Jigeeshu V. Divatia(Tata Memorial Hospital), Shripad Banavali(Tata Memorial Hospital), Rohini Hawaladar(Homi Bhabha National Institute), Minit Shah(Homi Bhabha National Institute), Srushti Shah(Homi Bhabha National Institute), Kavita Nawale, Shivakumar Thiagarajan(Tata Memorial Hospital), Vikram Chaudhari(Homi Bhabha National Institute), Anil D′Cruz(Apollo Hospitals), Oindrila Roy Chowdhury(Homi Bhabha National Institute)
Cited by 5
Related Papers
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
|Clinical and Translational Radiation Oncology|2018|932
ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies
|Intensive Care Medicine|2023|855
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694